← Back to patent-cliff list
Lidocaine/Heparin
Tier C — Watch / tradeLidocaine/Heparin
Urigen
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SCNA, SERPINC1
Indications (approved)：Urinary tract infection, 间质性膀胱炎, Infectious disease, 膀胱疾病, Pelvic pain
Regional status
US
Phase II
2006-01-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lidocaine/Heparin?
Approved indications include: Urinary tract infection, 间质性膀胱炎, Infectious disease, 膀胱疾病, Pelvic pain.
When does the Lidocaine/Heparin patent expire?
No public expiry year is available for Lidocaine/Heparin yet; this page updates once verified.
How do I get a quote for Lidocaine/Heparin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06